BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
Status: Recruiting
Location: See all (30) locations...
Study Type: Observational
SUMMARY
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Documented diagnosis of PH1, per physician's determination
Locations
United States
Arizona
Clinical Trial Site
RECRUITING
Phoenix
Washington, D.c.
Clinical Trial Site
COMPLETED
Washington D.c.
Massachusetts
Clinical Trial Site
RECRUITING
Boston
Minnesota
Clinical Trial Site
RECRUITING
Rochester
Ohio
Clinical Trial Site
RECRUITING
Cincinnati
Pennsylvania
Clinical Trial Site
RECRUITING
Pittsburgh
Texas
Clinical Trial Site
RECRUITING
Dallas
Clinical Trial Site
RECRUITING
Houston
Other Locations
Belgium
Clinical Trial Site
RECRUITING
Ghent
Clinical Trial Site
RECRUITING
Liège
Canada
Clinical Trial Site
RECRUITING
Hamilton
Clinical Trial Site
RECRUITING
Laurier
Clinical Trial Site
RECRUITING
Toronto
France
Clinical Trial Site
RECRUITING
Bordeaux
Clinical Trial Site
RECRUITING
Lyon
Clinical Trial Site
RECRUITING
Paris
Germany
Clinical Trial Site
RECRUITING
Berlin
Clinical Trial Site
RECRUITING
Cologne
Clinical Trial Site
RECRUITING
Hamburg
Israel
Clinical Trial Site
RECRUITING
Jerusalem
Italy
Clinical Trial Site
RECRUITING
Milan
Clinical Trial Site
RECRUITING
Orbassano
Clinical Trial Site
RECRUITING
Verona
Netherlands
Clinical Trial Site
RECRUITING
Amsterdam
Spain
Clinical Trial Site
RECRUITING
Barcelona
Clinical Trial Site
RECRUITING
Las Palmas
Clinical Trial Site
RECRUITING
Santa Cruz De Tenerife
Switzerland
Clinical Trial Site
RECRUITING
Bern
United Kingdom
Clinical Trial Site
RECRUITING
London
Clinical Trial Site
RECRUITING
London
Contact Information
Primary
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2021-12-13
Estimated Completion Date: 2028-09-01
Participants
Target number of participants: 200
Treatments
Patients with PH1
Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
Related Therapeutic Areas
Sponsors
Leads: Alnylam Pharmaceuticals